Long Jiang

Publications
CV
Public outreach and news

Articles

Article: MOLECULAR ONCOLOGY. 2024;18(2):317-335
High-content screening of drug combinations of an mPGES-1 inhibitor in multicellular tumor spheroids leads to mechanistic insights into neuroblastoma chemoresistance
Zaghmi A; Aybay E; Jiang L; Shang M; Steinmetz-Spah J; Wermeling F; Kogner P; Korotkova M; Ostling P; Jakobsson P-J; Seashore-Ludlow B; Larsson K
Article: SCIENTIFIC REPORTS. 2023;13(1):4583
MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia
Lerma Clavero A; Boqvist PL; Ingelshed K; Bosdotter C; Sedimbi S; Jiang L; Wermeling F; Vojtesek B; Lane DP; Kannan P
Article: CANCER RESEARCH COMMUNICATIONS. 2022;2(9):1075-1088
The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Pavenius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Article: ONCOSCIENCE. 2022;9:27-29
A CRISPR-p53 interactome with potential implications for clinical CRISPR/Cas9 use.
Jiang L; Wermeling F
Article: CANCER RESEARCH. 2022;82(1):36-45
CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Article: COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL. 2021;19:5360-5370
A rapid CRISPR competitive assay for in vitro and in vivo discovery of potential drug targets affecting the hematopoietic system
Shen Y; Jiang L; Iyer VS; Raposo B; Dubnovitsky A; Boddul SV; Kasza Z; Wermeling F
Journal article: CANCER IMMUNOLOGY RESEARCH. 2020;8(3_Supplement):a79
Abstract A79: Inhibition of p53-MDM2 protein interaction reduces tumor growth in a mouse melanoma model
Ingelshed K; Lianoudaki D; Lama D; Sohn S; Fritz N; Jiang L; Wermeling F; Karlsson M; Lane DP; Sedimbi SK
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(6):3103-3113
IL-4 controls activated neutrophil FcγR2b expression and migration into inflamed joints
Panda SK; Wigerblad G; Jiang L; Jimenez-Andrade Y; Iyer VS; Shen Y; Boddul SV; Guerreiro-Cacais AO; Raposo B; Kasza Z; Wermeling F
Article: CELL REPORTS. 2019;29(5):1074-1081.e5
Neutrophil Recruitment to Noninvasive MRSA at the Stratum Corneum of Human Skin Mediates Transient Colonization
Schulz A; Jiang L; de Vor L; Ehrstrom M; Wermeling F; Eidsmo L; Melican K
Article: BIOINFORMATICS. 2017;33(7):1099-1100
Green listed-a CRISPR screen tool
Panda SK; Boddul SV; Jimenez-Andrade GY; Jiang L; Kasza Z; Fernandez-Ricaud L; Wermeling F
Article: SCIENTIFIC REPORTS. 2017;7(1):354
A Novel Method of Evaluating Knee Joint Stability of Patients with Knee Osteoarthritis: Multiscale Entropy Analysis with A Knee-Aiming Task.
Zhou D; Zhang S; Zhang H; Jiang L; Zhang J; Fang J
Article: BEIJING DA XUE XUE BAO. YI XUE BAN = JOURNAL OF PEKING UNIVERSITY. HEALTH SCIENCES. 2016;48(2):257-262
[Evaluation of physical function for the end-stage osteoarthritis patient waiting for the total knee replacement].
Li ZC; Jiang L; Zhang S; Qin XY; White Pt DK; Hou YF; Zhou ZW; Lin JH

All other publications

Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S4 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S8 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S9 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S6 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S8 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S7 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S5 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Table S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S5 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S3 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S3 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Table S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S2 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S4 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S6 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S2 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S7 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Figure S9 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Preprint: BIORXIV. 2022
MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia
Clavero AL; Boqvist PL; Ingelshed K; Bosdotter C; Sedimbi S; Jiang L; Wermeling F; Vojtesek B; Lane DP; Kannan P
Thesis / dissertation: 2022
CRISPR-based drug target discovery : implications for CRISPR-based therapies
Jiang, Long
Preprint: BIORXIV. 2021
CRISPR enriches for cells with mutations in a p53-related interactome, and this can be inhibited
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Preprint: BIORXIV. 2021
A rapid CRISPR competitive assay forin vitroandin vivodiscovery of potential drug targets affecting the hematopoietic system
Shen Y; Jiang L; Iyer VS; Raposo B; Boddul S; Kasza Z; Wermeling F
Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2021;51:397
A rapid CRISPR competitive assay for in vitro and in vivo discovery of potential drug targets affecting the hematopoietic system
Shen Y; Jiang L; Iyer VS; Raposo B; Boddul SV; Kasza Z; Wermeling F
Conference publication: CANCER IMMUNOLOGY RESEARCH. 2020;8(3):71
Inhibition of p53-MDM2 protein interaction reduces tumor growth in a mouse melanoma model.
Ingelshed K; Lianoudaki D; Lama D; Sohn S; Fritz N; Jiang L; Wermeling F; Karlsson M; Lane DP; Sedimbi SK
Review: COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL. 2020;18:2237-2246
Designing custom CRISPR libraries for hypothesis-driven drug target discovery
Iyer VS; Jiang L; Shen Y; Boddul SV; Panda SK; Kasza Z; Schmierer B; Wermeling F
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):276
Deciphering the IL-4Rα regulating factor, produced during inflammation, by customized CRISPR screens
Panda SK; Kasza Z; Boddul S; Jimenez Y; Jiang L; Wigerblad G; Fernandez-Ricaud L; Wermeling F
Meeting abstract: OSTEOARTHRITIS AND CARTILAGE. 2015;23:A162
DISTINCT EXPRESSION OF SREBP-2 IN NORMAL AND OSTEOARTHRITIC CHONDROCYTES
Tao KS; Tang X; Wang B; Li JR; Jiang L; Lin HJ
Meeting abstract: OSTEOARTHRITIS AND CARTILAGE. 2015;23:A397-A398
DO PHYSICIANS TREAT OSTEOARTHRITIS PROPERLY IN CHINA: ANALYSIS OF 67382 OUT-PATIENTS FROM PEKING UNIVERSITY PEOPLE'S HOSPITAL
Zhang H; Jiang L; Li Z; Dong X; Zhong Q; Lin J
Meeting abstract: OSTEOARTHRITIS AND CARTILAGE. 2015;23:A373
THE EFFECT OF EDUCATION FOR DAILY PHYSICAL ACTIVITY LEVEL RECOVERY OF OSTEOARTHRITIS PATIENTS AFTER TOTAL KNEE ARTHROPLASTY. A PROSPECTIVE RANDOMIZED CONTROLLED CLINICAL TRIAL USING ACCELEROMETRY
Li Z; Jiang L; Lin J
Meeting abstract: OSTEOARTHRITIS AND CARTILAGE. 2015;23:A368
THE OBJECTIVE EVALUATION OF DAILY PHYSICAL ACTIVITY FOR KNEE OSTEOARTHRITIS PATIENTS AFTER TOTAL KNEE ARTHROPLASTY. A PROSPECTIVE CLINICAL TRIAL USING ACCELEROMETRY
Jiang L; Li Z; Lin J
Meeting abstract: OSTEOARTHRITIS AND CARTILAGE. 2015;23:A203
THE ANALYSIS OF ECONOMIC BURDEN FOR THE TREATMENT OF OSTEOARTHRITIS IN CHINA: ANALYSIS OF 67382 OUT-PATIENTS FROM PEKING UNIVERSITY PEOPLE'S HOSPITAL
Zhang H; Li Z; Jiang L; Dong X; Zhong Q; Lin J
Meeting abstract: OSTEOARTHRITIS AND CARTILAGE. 2014;22:S126
A NEW METHOD TO EVALUATE THE PROPRIOCEPTION IN KNEE OSTEOARTHRITIS: MULTISCALE ENTROPY
Jiang L; Zhang H; Zhou D; Lin J; Zhang J
Show more

Employments

Postdoctoral Studies, Department of Clinical Neuroscience, Karolinska Institutet, 2022-2025

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Medicine, Solna, Karolinska Institutet, 2022

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI